Skip to main content

Search

Oncology Research

Oncology and Haematology

Despite the incredible work of the oncology community across Europe, cancer remains the second leading cause of premature death in this region.1,2
At Janssen, we fiercely believe cancer is a challenge we can collectively overcome, and our ultimate aim is to make a cancer a manageable, even curable, condition.

We know that receiving a cancer diagnosis can be overwhelming and sparks fear. We are striving to change this, so that one day the words “you have cancer” will be less terrifying for patients to hear and less distressing for healthcare professionals to say and act upon.

Every cancer is different, each possessing unique challenges along the way.3 We are working to identify some of these challenges and focus precisely on the areas where we can make the most meaningful difference for people living with cancer, and the wider oncology community. To do this, we consistently integrate patients' perspectives into everything we do.

Our disease areas of focus include Haematological Malignancies such as Multiple myeloma, Chronic lymphocytic leukaemia (CLL), Mantle cell lymphoma (MCL) and Waldenström macroglobulinemia (WM). And Solid Tumour Malignancies such as Prostate Cancer, Lung Cancer and Urothelial Cancer.

References

1. World Health Organization Regional Office for Europe. Cancer data and statistics. Available at http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer. Last accessed May 2022.
2. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387.
3. Ogino S. et al. How many molecular subtypes? Implications of the unique tumour principle in personalized medicine. Expert Rev Mol Diagn. 2012; 12(6): 621–628.

CP-346500 | September 2022